| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication.
|
J Virol
|
2007
|
4.64
|
|
2
|
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.
|
Nat Immunol
|
2007
|
4.41
|
|
3
|
Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection.
|
J Virol
|
2008
|
3.24
|
|
4
|
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.
|
Arch Intern Med
|
2012
|
3.12
|
|
5
|
Characterization of CD4(+) CTLs ex vivo.
|
J Immunol
|
2002
|
3.10
|
|
6
|
Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution.
|
J Virol
|
2006
|
2.70
|
|
7
|
Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells.
|
J Virol
|
2009
|
2.51
|
|
8
|
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
|
AIDS
|
2007
|
2.27
|
|
9
|
STI and beyond: the prospects of boosting anti-HIV immune responses.
|
Trends Immunol
|
2002
|
2.12
|
|
10
|
Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection.
|
J Virol
|
2010
|
1.82
|
|
11
|
Impaired replication capacity of acute/early viruses in persons who become HIV controllers.
|
J Virol
|
2010
|
1.80
|
|
12
|
TCR beta-chain sharing in human CD8+ T cell responses to cytomegalovirus and EBV.
|
J Immunol
|
2008
|
1.70
|
|
13
|
Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis.
|
AIDS
|
2014
|
1.59
|
|
14
|
Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region.
|
J Biol Chem
|
2008
|
1.45
|
|
15
|
Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection.
|
Blood
|
2003
|
1.44
|
|
16
|
Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease.
|
Eur J Immunol
|
2009
|
1.43
|
|
17
|
Increased plasma interleukin-7 level correlates with decreased CD127 and Increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection.
|
J Infect Dis
|
2006
|
1.42
|
|
18
|
Escape from highly effective public CD8+ T-cell clonotypes by HIV.
|
Blood
|
2011
|
1.39
|
|
19
|
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
|
AIDS
|
2006
|
1.33
|
|
20
|
HLA footprints on human immunodeficiency virus type 1 are associated with interclade polymorphisms and intraclade phylogenetic clustering.
|
J Virol
|
2009
|
1.30
|
|
21
|
Transmission and long-term stability of compensated CD8 escape mutations.
|
J Virol
|
2008
|
1.29
|
|
22
|
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.
|
AIDS
|
2012
|
1.29
|
|
23
|
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.
|
J Clin Microbiol
|
2013
|
1.25
|
|
24
|
HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis.
|
Blood
|
2011
|
1.25
|
|
25
|
Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection.
|
J Virol
|
2006
|
1.23
|
|
26
|
Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expression.
|
J Immunol
|
2012
|
1.23
|
|
27
|
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40).
|
J Immunol
|
2009
|
1.22
|
|
28
|
Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques.
|
J Virol
|
2013
|
1.21
|
|
29
|
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection.
|
Immunology
|
2013
|
1.19
|
|
30
|
Frequent transmission of cytotoxic-T-lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A24-positive Japanese population.
|
J Virol
|
2004
|
1.18
|
|
31
|
Chromatin-associated protein kinase C-θ regulates an inducible gene expression program and microRNAs in human T lymphocytes.
|
Mol Cell
|
2011
|
1.15
|
|
32
|
Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells.
|
Nucleic Acids Res
|
2011
|
1.15
|
|
33
|
The IL-7/IL-7 receptor axis: understanding its central role in T-cell homeostasis and the challenges facing its utilization as a novel therapy.
|
Curr Drug Targets
|
2006
|
1.14
|
|
34
|
Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection.
|
Virology
|
2002
|
1.14
|
|
35
|
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir.
|
AIDS
|
2011
|
1.13
|
|
36
|
Rates of transmission of antiretroviral drug resistant strains of HIV-1.
|
J Clin Virol
|
2003
|
1.12
|
|
37
|
First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection.
|
Virology
|
2003
|
1.12
|
|
38
|
HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.
|
J Virol
|
2014
|
1.09
|
|
39
|
Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty.
|
Immunol Cell Biol
|
2003
|
1.08
|
|
40
|
Persistent survival of prevalent clonotypes within an immunodominant HIV gag-specific CD8+ T cell response.
|
J Immunol
|
2010
|
1.08
|
|
41
|
A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1.
|
AIDS Res Hum Retroviruses
|
2005
|
1.08
|
|
42
|
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).
|
J Acquir Immune Defic Syndr
|
2006
|
1.08
|
|
43
|
Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription.
|
Microbes Infect
|
2009
|
1.07
|
|
44
|
Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial.
|
AIDS
|
2010
|
1.06
|
|
45
|
Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples.
|
Clin Vaccine Immunol
|
2006
|
1.05
|
|
46
|
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
|
J Infect Dis
|
2011
|
1.05
|
|
47
|
Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals.
|
J Virol
|
2011
|
1.05
|
|
48
|
Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification.
|
J Clin Virol
|
2010
|
1.04
|
|
49
|
Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection.
|
Blood
|
2005
|
1.04
|
|
50
|
HIV vaccines: progress to date.
|
Drugs
|
2011
|
1.04
|
|
51
|
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection.
|
J Acquir Immune Defic Syndr
|
2008
|
1.02
|
|
52
|
Promoter-targeted siRNAs induce gene silencing of simian immunodeficiency virus (SIV) infection in vitro.
|
Mol Ther
|
2008
|
0.99
|
|
53
|
The search for an HIV cure: tackling latent infection.
|
Lancet Infect Dis
|
2013
|
0.98
|
|
54
|
No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001.
|
AIDS
|
2003
|
0.96
|
|
55
|
Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific.
|
RNA Biol
|
2011
|
0.94
|
|
56
|
CD127+CCR5+CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia virus and precede development of interleukin-2+ memory CD4+ T cells.
|
J Virol
|
2006
|
0.94
|
|
57
|
Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcgammaRIIa genotype.
|
AIDS
|
2010
|
0.94
|
|
58
|
Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.
|
J Virol
|
2012
|
0.93
|
|
59
|
Dyslipidemia due to retroviral protease inhibitors.
|
Nat Med
|
2002
|
0.93
|
|
60
|
HIV immune escape at an immunodominant epitope in HLA-B*27-positive individuals predicts viral load outcome.
|
J Immunol
|
2010
|
0.92
|
|
61
|
Transcriptional regulation by promoter targeted RNAs.
|
Curr Top Med Chem
|
2009
|
0.92
|
|
62
|
Characterization of transcription factor phenotypes within antigen-specific CD4+ T cells using qualitative multiplex single-cell RT-PCR.
|
PLoS One
|
2013
|
0.91
|
|
63
|
Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers.
|
AIDS
|
2013
|
0.90
|
|
64
|
miRNAs and HIV: unforeseen determinants of host-pathogen interaction.
|
Immunol Rev
|
2013
|
0.90
|
|
65
|
Optimization of peptide linker length in production of MHC class II/peptide tetrameric complexes increases yield and stability, and allows identification of antigen-specific CD4+T cells in peripheral blood mononuclear cells.
|
Eur J Immunol
|
2002
|
0.90
|
|
66
|
T-lymphocyte perturbation following large-scale apheresis and hematopoietic stem cell transplantation in HIV-infected individuals.
|
Clin Immunol
|
2012
|
0.88
|
|
67
|
Safety, immunogenicity and efficacy of peptide-pulsed cellular immunotherapy in macaques.
|
J Med Primatol
|
2008
|
0.88
|
|
68
|
Regulatory T cells in HIV infection: who's suppressing what?
|
Curr HIV/AIDS Rep
|
2008
|
0.88
|
|
69
|
Low pre-infection levels and loss of central memory CD4+ T cells may predict rapid progression in SIV-infected pigtail macaques.
|
Virology
|
2008
|
0.88
|
|
70
|
Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing.
|
Mol Ther Nucleic Acids
|
2013
|
0.87
|
|
71
|
Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
|
AIDS Res Hum Retroviruses
|
2009
|
0.87
|
|
72
|
Does the presence of anti-HIV miRNAs in monocytes explain their resistance to HIV-1 infection?
|
Blood
|
2009
|
0.87
|
|
73
|
Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
|
AIDS
|
2015
|
0.87
|
|
74
|
Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting.
|
AIDS Res Hum Retroviruses
|
2013
|
0.86
|
|
75
|
Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells.
|
PLoS One
|
2012
|
0.86
|
|
76
|
The role of microRNAs in HIV-1 pathogenesis and therapy.
|
AIDS
|
2012
|
0.86
|
|
77
|
Role of interleukin-2 in patients with HIV infection.
|
Drugs
|
2010
|
0.86
|
|
78
|
The microRNA-9/B-lymphocyte-induced maturation protein-1/IL-2 axis is differentially regulated in progressive HIV infection.
|
Eur J Immunol
|
2012
|
0.86
|
|
79
|
Immune activation and immune aging in HIV infection.
|
Curr Opin HIV AIDS
|
2016
|
0.85
|
|
80
|
IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers.
|
Cytokine
|
2010
|
0.84
|
|
81
|
A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study.
|
PLoS Clin Trials
|
2006
|
0.84
|
|
82
|
Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.
|
PLoS One
|
2012
|
0.84
|
|
83
|
The majority of HIV type 1 DNA in circulating CD4+ T lymphocytes is present in non-gut-homing resting memory CD4+ T cells.
|
AIDS Res Hum Retroviruses
|
2013
|
0.83
|
|
84
|
Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency.
|
PLoS One
|
2013
|
0.83
|
|
85
|
miR-155 is differentially expressed in Treg subsets, which may explain expression level differences of miR-155 in HIV-1 infected patients.
|
Blood
|
2012
|
0.83
|
|
86
|
High viral fitness during acute HIV-1 infection.
|
PLoS One
|
2010
|
0.82
|
|
87
|
Validation of RNA-based molecular clonotype analysis for virus-specific CD8+ T-cells in formaldehyde-fixed specimens isolated from peripheral blood.
|
J Immunol Methods
|
2007
|
0.82
|
|
88
|
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
|
AIDS
|
2012
|
0.82
|
|
89
|
Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials.
|
Hum Vaccin
|
2006
|
0.82
|
|
90
|
A culture amplified multi-parametric intracellular cytokine assay (CAMP-ICC) for enhanced detection of antigen specific T-cell responses.
|
J Immunol Methods
|
2009
|
0.82
|
|
91
|
Temporal effect of HLA-B*57 on viral control during primary HIV-1 infection.
|
Retrovirology
|
2013
|
0.81
|
|
92
|
A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection.
|
AIDS Res Hum Retroviruses
|
2010
|
0.81
|
|
93
|
A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays.
|
Tuberculosis (Edinb)
|
2012
|
0.80
|
|
94
|
Regulatory T cells in HIV infection: who's suppressing what?
|
Curr Infect Dis Rep
|
2008
|
0.80
|
|
95
|
Human antigen-specific CD4⁺ CD25⁺ CD134⁺ CD39⁺ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses.
|
Eur J Immunol
|
2014
|
0.80
|
|
96
|
Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action.
|
PLoS Comput Biol
|
2013
|
0.79
|
|
97
|
MicroRNA modulation of key targets associated with T cell exhaustion in HIV-1 infection.
|
Curr Opin HIV AIDS
|
2014
|
0.79
|
|
98
|
Progressive activation of CD127+132- recent thymic emigrants into terminally differentiated CD127-132+ T-cells in HIV-1 infection.
|
PLoS One
|
2012
|
0.79
|
|
99
|
The role of T cell immunity in HIV-1 infection.
|
Curr Opin Virol
|
2013
|
0.79
|
|
100
|
Cytokine therapies in HIV-1 infection: present and future.
|
Expert Rev Anti Infect Ther
|
2003
|
0.79
|
|
101
|
Early immune adaptation in HIV-1 revealed by population-level approaches.
|
Retrovirology
|
2014
|
0.79
|
|
102
|
Changes in metabolic, inflammatory and coagulation biomarkers after HIV seroconversion--the Health in Men (HIM) Biomarker Substudy.
|
Antivir Ther
|
2012
|
0.78
|
|
103
|
Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity.
|
AIDS
|
2006
|
0.78
|
|
104
|
Control of early HIV-1 infection associates with plasmacytoid dendritic cell-reactive opsonophagocytic IgG antibodies to HIV-1 p24.
|
AIDS
|
2016
|
0.78
|
|
105
|
The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.
|
AIDS
|
2016
|
0.77
|
|
106
|
Serial study of lymph node cell subsets using fine needle aspiration in pigtail macaques.
|
J Immunol Methods
|
2013
|
0.76
|
|
107
|
Reply to "Issues on results of the external quality assessment for proviral DNA testing of HIV-1 Tropism in the Maraviroc Switch collaborative study".
|
J Clin Microbiol
|
2013
|
0.75
|
|
108
|
The modern ART of HIV infection management: towards a tailored approach to maximize CD4 T cell reconstitution.
|
Clin Infect Dis
|
2005
|
0.75
|
|
109
|
Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.
|
PLoS Pathog
|
2016
|
0.75
|
|
110
|
Immunogenicity assay validation for an HIV vaccine trial: high IFNγ+/IL-2+ CD8+ T cells background in healthy Thais.
|
Vaccine
|
2011
|
0.75
|
|
111
|
RNA duplexes in transcriptional regulation.
|
Biomol Concepts
|
2010
|
0.75
|
|
112
|
Impact of allogeneic hematopoietic stem cell transplantation on the HIV reservoir and immune response in three HIV infected individuals.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|